Immucor Inc.
Norcross, GA
- UEI
- KV8AGJX7NMZ7
- CAGE
- 64527
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
- Warren, NJ UB25FLCNAPL3
- VXJRVAYZFTK3
- FSB6WKGDWX46
- D1UJXS2NKBJ1
-
- SAM.gov registration date
- Physical address
- 3130 Gateway Dr, Norcross, GA 30071, USA
- Website
- werfen.com
- Founded
- 1966
- Employees
- 5K-10K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $28,182 |
| FY2026 | $922,974 |
| FY2025 | $3,493,188 |
| FY2024 | $3,832,616 |
| FY2023 | $4,766,430 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $558,691 | |
| 2 | Department of Veterans Affairs | $402,786 | |
| 3 | Defense Logistics Agency | $51 |
Contract vehicles
Expired vehicles (2)
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| US Customer Operations | Brea, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Ortho-Clinical Diagnostics, Inc. | Raritan, NJ | 334516 Analytical Laboratory Instrument Manufacturing |
| Grifols Diagnostic Solutions Inc. | Emeryville, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Quidelortho Sales Company, LLC | San Diego, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Alba Bioscience, Inc. | Chicago, IL | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Immucor Inc., headquartered in Norcross, Georgia, manufactures in vitro diagnostic reagents, blood bank analyzers, and transfusion compatibility testing equipment sold primarily as a prime contractor to federal healthcare agencies under full-and-open competition, with no SBA set-aside designations across its federal footprint.
Immucor's federal customer base concentrates heavily in military and veterans' healthcare. The Defense Health Agency anchors the portfolio with 61 awards worth $25.7 million in combined potential value, followed by the Department of Navy Bureau of Medicine and Surgery (370 awards, $18.9 million), Department of Army Medical Command (182 awards, $16.8 million), and the Department of Veterans Affairs' Veterans Integrated Service Network 12 (106 awards, $16.5 million). These four customers account for 53% of the vendor's $165.3 million combined potential value across 5,467 awards. The Navy and Army dominate by award count (552 awards together), while the Defense Health Agency leads by dollar magnitude, reflecting larger-value equipment and supply contracts for automated blood bank analyzers and reagent systems. Immucor draws from 45 distinct federal customer agencies, but concentration among the top five is decisive: the vendor depends on Defense Health Agency, Navy, Army, Veterans Affairs VISN 12, and Air Force Air Education and Training Command for the majority of its revenue stream.
The vendor's vehicle portfolio is anchored by the GSA Schedule 65-VII (In Vitro Diagnostics, Reagents, Test), which has generated 2,856 task orders worth $84.5 million combined potential value — the overwhelming majority of Immucor's federal work. Immucor also holds a $1,020,000 single-award Blanket Purchase Agreement with the Defense Health Agency through March 2027 and a matching $1,020,000 BPA with Air Education and Training Command through March 2027, both for purchase of reagents and blood testing products. A $634,051.95 indefinite delivery contract with the Defense Health Agency runs through September 2027 for FSC 6550 in vitro diagnostic reagents. The vendor holds single-award IDIQs with Veterans Integrated Service Network 9 ($127,199.10 ceiling, through July 2026) and the Air Combat Command ($44,842.80 ceiling under SBIR Phase III, through September 2025). All work flows through these parent vehicles as task orders and delivery orders; the vendor operates exclusively as a prime, with no subcontract footprint reported.
Immucor's contract portfolio has contracted meaningfully year over year — 38 awards in 2022, declining to 25 in 2024 and 7 in 2025, with only 3 awards recorded in 2026 through August. Only three awards face ultimate completion within the next twenty-four months, carrying $813 thousand in combined potential value and minimal recompete risk relative to the vendor's current run rate. The inventory of small, recurring purchase orders and delivery orders against the GSA Schedule 65-VII suggests a mature, stable supply relationship with federal health providers rather than a growth trajectory. The vendor's core capability is the recurring supply of blood bank reagents, control cells, and diagnostic test kits to support transfusion medicine across military, VA, and Indian Health Service medical facilities; representative recent work includes a $1,020,000 Defense Health Agency BPA for blood testing products, a $535,165.00 purchase order from Defense Health Agency for two automated blood bank analyzers and supplies to William Beaumont Army Medical Center through 2028, and a $499,276.70 delivery order from Veterans Integrated Service Network 21 for blood bank analyzers and services through 2029. The vendor also supplies specialized reagent items in sub-$100,000 quantities across dozens of VA regional service networks on a standing-order basis.
Immucor's corporate structure includes four named subsidiaries — Immucor Medizinische Diagnosti, Immucor S.l., Bioarray Solutions LTD, and Immucor Italia S.P.A. — which signal international operations and possible capability breadth in analytical laboratory instruments and equipment maintenance, though the federal contract footprint reflects pure reagent and blood bank equipment supply with no visible subcontracting or sub-award activity.
Quick answers
Is Immucor Inc. registered in SAM.gov?
Yes. Immucor Inc.'s SAM.gov registration is active through March 20, 2027.
Which contract vehicles does Immucor Inc. hold?
Immucor Inc. holds a place on 3 federal contract vehicles, including MAS.
How much has Immucor Inc. received in federal contracts?
Federal contracts obligated $3,493,188 to Immucor Inc. in fiscal year 2025 and $13,043,391 in fiscal years 2023 through 2027.
How does Immucor Inc. rank among federal contractors?
Immucor Inc. ranked #11 in NAICS 325413, #22 in PSC 6550 and #23 in PSC W066 in FY2025.
What is Immucor Inc.'s most recent federal award?
Immucor Inc.'s most recent federal contract award is Blood bank analyzer for the washington DC VA medical center (36C24526F0359), from Veterans Integrated Service Network 5 (VHA), on August 20, 2026.
On GovTribe
See Immucor Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors